ClinicalTrials.gg
CompletedNCT03084133EDUCANCOLAGEUpdated Sep 26, 2019

Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives

An interventional study of Therapeutic Education Strategy in Cancer Colorectal, sponsored by University Hospital, Tours. Completed at 8 sites in France. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-26.

Sponsored by University Hospital, Tours · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced adenoma before age 60, total colonoscopy is the recommended screening test. In France, the rate of screening colonoscopy in this population at high risk of CRC is insufficient, which limits the effectiveness of this targeted screening.

The main reason for this low participation rate is that most patients undergoing RCC or advanced adenoma are unaware of the family implications of their diagnosis and therefore reluctant to disseminate this information to their patients Related matters. The need for a better perception of the personal risk of CRC in first-degree relatives of patients with CRC or advanced adenoma, with the expected coronary adherence to increasing screening, requires a good understanding of risk through Clear, adapted and comprehensible information that can be relayed personally by the case-index.

The objective of this project is to develop a personalized prevention and screening program for the JRC in order to meet the needs of the relatives of the sick. The means of intervention that will be implemented respond to the need to better take into account the level of CRC risk in a family-based CRC screening and prevention approach adapted to a high-risk CRC group characterized by Family history at the first stage of CRC or advanced adenoma and, consequently, to improve the information of the subjects concerned by screening and prevention of CRC.

The aim of the case-index education is to induce its intervention with its relatives to promote CCR screening. The use of the index case, as a means of providing information to relatives, implies an educational and psychological approach, based on evidence, but adapted and personalized.

Read the detailed description

The relative risk of colorectal cancer (CRC) is increased in first-degree relatives of patients with CRC or advanced adenoma. In the high-risk CCR population defined by a family history at the first stage of CRC or advanced adenoma before age 60, total colonoscopy is the recommended screening test. In France, the rate of screening colonoscopy in this population at high risk of CRC is insufficient, which limits the effectiveness of this targeted screening.

02

Conditions studied

  • Cancer Colorectal

Browse trials for

Keywords

  • Therapeutic education strategy
03

In context

Colonic Neoplasms

1,485 studies on the registry are indexed under Colonic Neoplasms; 362 are open to participants now.

This study's enrollment of 68 is below the median of 89 across 1,067 interventional studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 306 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

List of inclusion criteria

Index case:

  • Patients with colorectal adenocarcinoma or advanced adenoma diagnosed (definition of advanced adenoma (Winawer, 2006): adenoma of diameter ≥ 10 mm and / or severe dysplasia and / or with a villous contingent).
  • Patients with at least one relative of the first degree belonging to the target population of the screening strategy evaluated (between 40 and 75 years of age and less than 10 years of age of the case-index) and residing in France.
  • Affiliation of the patient to a social security scheme (including CMU).
  • Understanding of the French language.

Related:

  • They correspond to the target population at high risk of colorectal cancer targeted by this program of promotion of colonoscopy screening:
  • Subjects related to 1st degree to the index case and in contact with it.
  • Age between 40 and 75 years of age or less than 10 years of age of the index case.
  • Resides in France

List of exclusion Criteria :

Index case :

  • Chronic inflammatory bowel disease.
  • Genetic predisposition syndrome identified with colorectal cancer (Lynch syndrome, familial polyposis linked to the APC and MYH genes).
  • Patient's knowledge of a first-degree relative with colorectal adenocarcinoma or advanced adenoma.
  • Isolated patient of his / her first-degree relatives and not wishing to re-establish contact with them.
  • Advanced colorectal cancer with a life expectancy \<6 months and / or a WHO ≥ 2 general condition.
  • Transmission of information to the family already carried out.

Related :

- Not applicable

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Therapeutic Education Strategy

    Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account. Intervention 'Therapeutic Education Strategy'

    Behavioral: Therapeutic Education Strategy

  • No intervention
    Control group

    Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice

Interventions

  • BehavioralTherapeutic Education Strategy

    In the experimental arm of the study ("intervention group"), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the "intention" of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a "competence" approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002).

06

What researchers measure

Primary outcomes

  1. Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.

    Participation rate in screening colonoscopy for first-degree relatives of patients with RCC or advanced adenoma.

    Time frame: 12 MONTHS

Secondary outcomes

  1. Psychological determinants (quality of relationship with relatives, motivation to inform relatives) that can condition the enrollment in the education program.

    Psychological determinants (quality of relationship with relatives, motivation to inform relatives) that can condition the enrollment in the education program.

    Time frame: 12 MONTHS

  2. Social and demographic factors in index cases associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    Social and demographic factors in index cases associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    Time frame: 12 MONTHS

  3. Social and demographic factors associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    Social and demographic factors associated with screening colonoscopy in related subjects: age, sex, educational level, socio-professional category.

    Time frame: 12 MONTHS

  4. How to access screening colonoscopy: pathway (public or private), direct access to the gastroenterologist or through the attending physician.

    How to access screening colonoscopy: pathway (public or private), direct access to the gastroenterologist or through the attending physician.

    Time frame: 12 MONTHS

  5. Time to access the colonoscopy (time between the procedure and the completion of the screening colonoscopy).

    Time to access the colonoscopy (time between the procedure and the completion of the screening colonoscopy).

    Time frame: 2 MONTHS

  6. Rate of colorectal cancer.

    Rate of colorectal cancer.

    Time frame: 12 MONTHS

  7. Rate of advanced adenomas.

    Rate of advanced adenomas.

    Time frame: 12 MONTHS

  8. Detection rate of scallop lesions.

    Detection rate of scallop lesions.

    Time frame: 12 MONTHS

  9. Rate of complications in screening colonoscopies.

    Rate of complications in screening colonoscopies.

    Time frame: 12 MONTHS

  10. Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale.

    Quality criteria for screening colonoscopy using the following parameters: visualization rate of the bottom of the colon, the withdrawal time of the colonoscope (Withdrawal time), quality of the colic preparation using the Boston scale.

    Time frame: 12 MONTHS

07

Study locations

8 sites
  • Service d'Hépatogastro-entérologie CHU ANGERS
    Angers, France
  • Service d'Hépatogastro-entérologie CHG BLOIS
    Blois, 41 000, France
  • Service d'Hépatogastro-entérologie CHG de DREUX
    Dreux, France
  • Service de Médecine CHG de Loches
    Loches, France
  • Service d'Hépatogastro-entérologie CHU de NANTES
    Nantes, France
  • Service d'Hépatogastro-entérologie CHR d'Orléans
    Orléans, 45067, France
  • Service d'Hépatogastro-entérologie CHU POITIERS
    Poitiers, 86 000, France
  • Service d'Hépatogastro-entérologie CHRU de TOURS
    Tours, 37044, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Jan 2019, 21 months.

Of 290 non-industry interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 60. This study's 21 months is below that.

Counting every sponsor, half of 300 studies reached it within 32 months; a quarter within 18 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2017
First posted
Mar 20, 2017
StartActual
Apr 10, 2017
Primary completionActual
Jan 19, 2019
CompletionActual
Jan 19, 2019
Last update
Sep 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03084133
Collaborators
University Hospital, Angers, Nantes University Hospital, Centre Hospitalier de Dreux, Hospital BLOIS, Hospital LOCHES, Poitiers University Hospital, University of New Orleans, Clinic LE MANS
Responsible party
Sponsor
First posted
Mar 20, 2017
Start date
Apr 10, 2017
Primary completion
Jan 19, 2019
Completion
Jan 19, 2019
Last update
Sep 26, 2019

Study contacts

CAROLI BOSC Françis- Xavier, Pr
principal investigator · University Hospital, Angers
MATYSIAK-BUDNIK Tamara, Pr
principal investigator · Nantes University Hospital
LANDAU Alain, Dr
principal investigator · CHG DREUX
GARGOT Denis, Dr
principal investigator · CHG BLOIS
BARBIEUX Jean- Pierre, Dr
principal investigator · CHG LOCHES
TOUGERON David, Pr
principal investigator · CHU Poitiers
LEGOUX Jean- Louis, Dr
principal investigator · CHR ORLEANS
BOURGEOIS Hugues, Dr
principal investigator · Clinic Victor Hugo LE MANS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion